Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, Murray ME, Price JC, Salloway SP, Weber CJ, Carrillo MC, Johnson KA. Rabinovici GD, et al. Among authors: weber cj. J Nucl Med. 2025 Jan 8:jnumed.124.268756. doi: 10.2967/jnumed.124.268756. Online ahead of print. J Nucl Med. 2025. PMID: 39778970
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, Murray ME, Price JC, Salloway SP, Weber CJ, Carrillo MC, Johnson KA. Rabinovici GD, et al. Among authors: weber cj. Alzheimers Dement. 2025 Jan 8. doi: 10.1002/alz.14338. Online ahead of print. Alzheimers Dement. 2025. PMID: 39776249 Review.
Alzheimer's disease drug development in an evolving therapeutic landscape.
Weninger S, Irizarry MC, Fleisher AS, León T, Maruff P, Miller DS, Seleri S, Carrillo MC, Weber CJ. Weninger S, et al. Among authors: weber cj. Alzheimers Dement (N Y). 2024 Nov 30;10(4):e70015. doi: 10.1002/trc2.70015. eCollection 2024 Oct-Dec. Alzheimers Dement (N Y). 2024. PMID: 39748838 Free PMC article.
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice.
Jack CR, Graf A, Burnham SC, Doty EG, Moebius HJ, Montenigro P, Siemers E, Sink KM, Shaw LM, Hansen CT, Wildsmith KR, Mahinrad S, Carrillo MC, Weber CJ. Jack CR, et al. Among authors: weber cj. Alzheimers Dement (N Y). 2024 Dec 14;10(4):e70013. doi: 10.1002/trc2.70013. eCollection 2024 Oct-Dec. Alzheimers Dement (N Y). 2024. PMID: 39748835 Free PMC article.
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
Rentz DM, Aisen PS, Atri A, Hitchcock J, Irizarry M, Landen J, Matthews BR, Miller DS, Mahinrad S, Napoli S, Okhravi HR, Petersen RC, Siemers ER, Weber CJ, Weisman DC, Carrillo MC. Rentz DM, et al. Among authors: weber cj. Alzheimers Dement. 2024 Nov;20(11):8162-8171. doi: 10.1002/alz.14199. Epub 2024 Sep 22. Alzheimers Dement. 2024. PMID: 39306695 Free PMC article.
174 results